Announcements
- Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
- Assembly Biosciences Announces $12.6 Million in Equity Financings
- Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
- Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
- Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
- Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
- Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
- Assembly Biosciences Announces Effective Date of Reverse Stock Split
- Assembly Biosciences Provides Anticipated Development Milestones for 2024
- Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Thursday, Assembly Biosciences Inc (V7B:STU) closed at 10.85, 57.52% above the 52 week low of 6.89 set on Nov 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.85 |
---|---|
High | 10.85 |
Low | 10.85 |
Bid | 10.85 |
Offer | 11.70 |
Previous close | 11.85 |
Average volume | 1.98k |
---|---|
Shares outstanding | 6.12m |
Free float | 4.12m |
P/E (TTM) | -- |
Market cap | 74.32m USD |
EPS (TTM) | -11.22 USD |
Data delayed at least 15 minutes, as of Jul 04 2024.
More ▼